HomeCompareVCST vs JNJ

VCST vs JNJ: Dividend Comparison 2026

VCST yields 1000000.00% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VCST wins by $4.7683925249533696e+36M in total portfolio value
10 years
VCST
VCST
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full VCST calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — VCST vs JNJ

📍 VCST pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVCSTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VCST + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VCST pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VCST
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, VCST beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VCST + JNJ for your $10,000?

VCST: 50%JNJ: 50%
100% JNJ50/50100% VCST
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VCST
No analyst data
Altman Z
-22.9
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VCST buys
0
JNJ buys
0
No recent congressional trades found for VCST or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVCSTJNJ
Forward yield1000000.00%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.7683925249533696e+36M$30.5K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$4,749.88
Total dividends collected$4.7683311610149396e+36M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VCST vs JNJ ($10,000, DRIP)

YearVCST PortfolioVCST Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,594$274.49+$100.00MVCST
2$934,786,450,701$934,679,439,252.34$11,294$360.69+$934786.44MVCST
3$8,165,787,108,578,292$8,164,786,887,076,042.00$12,133$476.91+$8165787108.57MVCST
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$13,156$635.42+$66665884190957.63MVCST
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$14,432$854.61+$508662171058048128.00MVCST
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$16,056$1,162.76+$3.62723524842849e+21MVCST
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$18,175$1,604.53+$2.417368115915061e+25MVCST
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$21,009$2,252.68+$1.5056740286145463e+29MVCST
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$24,911$3,229.73+$8.764771002818475e+32MVCST
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$30,458$4,749.88+$4.7683925249533696e+36MVCST

VCST vs JNJ: Complete Analysis 2026

VCSTStock

ViewCast.com, Inc., doing business as ViewCast Corporation, develops hardware and software for the capture, management, and delivery of video over IP and mobile networks. The company's products include Osprey Video line of capture cards for video acquisition/capture/streaming; and Niagara Streaming Systems and Software, which provide pre-configured, plug-and-play solutions enabling the user to encode and stream audio and video over the Internet or corporate network. It also provides professional services and support; and complementary products and technologies from third party providers. The company serves various markets, including broadcasters, content delivery networks, and narrowcasters; federal, state, and local governments; small, medium, and large enterprises; mobile and cable providers; education and training; retail and consumer package goods; digital signage integrators; and other industry verticals, such as advertising, medical, and insurance. ViewCast.com, Inc. markets and sells its products and professional services directly to end-users or through indirect channels comprising original equipment manufacturers, value-added resellers, resellers, distributors, and computer system integrators worldwide. The company was formerly known as MultiMedia Access Corporation and changed its name to ViewCast.com, Inc. in April 1999. ViewCast.com, Inc. was founded in 1994 and is headquartered in Plano, Texas.

Full VCST Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this VCST vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VCST vs SCHDVCST vs JEPIVCST vs OVCST vs KOVCST vs MAINVCST vs ABBVVCST vs MRKVCST vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.